Summary The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population […]
Summary There is a great deal of uncertainty surrounding the prevalence of hepatitis delta virus among people living with hepatitis B virus at the population level. In this study, we aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower […]
Summary The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infections by 2030. However, the HBV prevalence in Western countries, where the historical prevalence is low and highly impacted by immigration trends, remains uncertain making planning difficult. We aimed to develop a more accurate estimate of HBV prevalence and identify key […]
Summary Chronic hepatitis B infection (defined as sustained detection of hepatitis B virus [HBV] surface antigen [HBsAg] protein in serum) is a leading cause of cirrhosis, hepatocellular carcinoma and liver-related deaths. A situation analysis carried out by the Swiss Federal Office of Public Health estimated the HBsAg prevalence in Switzerland to be 0.53% (95% CI: […]
Summary Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts […]
Summary Egypt used to have one of the highest prevalences of HCV infection worldwide. The Egyptian Ministry of Health launched a national campaign for the detection and management of HCV to reduce its burden. This study aims to carry out a cost-effectiveness analysis to evaluate the costs and benefits of the Egyptian national screening and […]
Summary High unit prices of treatments limit access. For epidemics like that of hepatitis C virus (HCV), reduced treatment access increases prevalence and incidence, making the infectious disease increasingly difficult to manage. The objective of the current study was to construct and test an alternative pricing model, the Payer License Agreement (PLA), and determine whether […]
Resumen En julio de 2020, el Gobierno mexicano inició el Programa Nacional para la Eliminación de la Hepatitis C (VHC) en virtud de un acuerdo de adquisición, asegurando el acceso universal y gratuito a la detección, el diagnóstico y el tratamiento del VHC para 2020-2022. Este análisis cuantifica la carga clínica y económica del VHC (MXN) en caso de continuación (o finalización) del acuerdo. Se realizó un modelado y […]
Resumen La Organización Mundial de la Salud recomienda la vacunación universal contra el virus de la hepatitis B (VHB) al nacer, pero solo tres provincias y territorios de Canadá ofrecen la vacunación al nacer y los niños nacidos en Canadá en Ontario contraen el VHB antes de la vacunación en la adolescencia. Buscamos determinar si la vacunación contra el VHB al nacer y/o en la infancia es rentable. Utilizamos un modelo dinámico […]
Resumen En 2019, Estados Unidos no estaba en vías de alcanzar los objetivos de eliminación debido a la creciente incidencia y las barreras de tratamiento. En 2020, la pandemia de COVID-19 interrumpió los servicios de atención de la salud contra el VHC a nivel mundial y en Estados Unidos. A medida que se normalizan los servicios de atención de la salud, existe una necesidad urgente de reevaluar el progreso y evaluar escenarios que restablezcan […]
Spanish 
English 
French 
Russian 
Arabic